Cartalax — Khavinson bioregulator — cartilage / connective tissue
Cartalax targets cartilage and connective tissue. Proposed to restore chondrocyte gene expression programs, promote proteoglycan synthesis, reduce matrix metalloproteinase activity, and support joint health. Very limited published clinical data.
Overview
This page is part of Hormonaly's evidence-graded compound library. All clinical claims are linked to peer-reviewed sources via our dual-layer citation verification pipeline.
Compound Class
Khavinson bioregulator — cartilage / connective tissue
Mechanism of Action
Cartalax targets cartilage and connective tissue. Proposed to restore chondrocyte gene expression programs, promote proteoglycan synthesis, reduce matrix metalloproteinase activity, and support joint health. Very limited published clinical data.
Regulatory Status
Not FDA approved. Research peptide.
Evidence Level
Very Low — limited published data. Evidence from Khavinson group only.